Q4 EPS Estimates for OTCMKTS:BSEM Increased by Analyst

BioStem Technologies, Inc. (OTCMKTS:BSEM) – Stock analysts at Zacks Small Cap lifted their Q4 2024 earnings per share (EPS) estimates for shares of BioStem Technologies in a research report issued to clients and investors on Friday, November 15th. Zacks Small Cap analyst B. Sorensen now expects that the company will post earnings of $0.37 per share for the quarter, up from their previous forecast of $0.32. The consensus estimate for BioStem Technologies’ current full-year earnings is $1.13 per share. Zacks Small Cap also issued estimates for BioStem Technologies’ Q1 2026 earnings at $0.52 EPS, Q2 2026 earnings at $0.57 EPS, Q3 2026 earnings at $0.61 EPS and FY2026 earnings at $2.39 EPS.

BioStem Technologies Trading Down 20.2 %

OTCMKTS:BSEM opened at 13.90 on Monday. The firm’s fifty day simple moving average is 13.52 and its 200 day simple moving average is 10.73. BioStem Technologies has a twelve month low of 2.34 and a twelve month high of 28.26. The firm has a market capitalization of $231.02 million, a price-to-earnings ratio of 20.44 and a beta of -0.36.

BioStem Technologies (OTCMKTS:BSEM) last posted its quarterly earnings results on Tuesday, November 12th. The company reported 0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of 0.31 by 0.01. The firm had revenue of 82.56 million for the quarter, compared to analysts’ expectations of 78.22 million.

About BioStem Technologies

BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases.